ResMed Inc. vs Utilities Select Sector SPDR Fund — how do they compare? ResMed Inc. trades at $230.05 (market cap $31.89B), while Utilities Select Sector SPDR Fund trades at $41.39 (market cap $23.60B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.16% dividend while Utilities Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| RMD | XLU | |
|---|---|---|
Market Cap | $31.89B | $23.60B |
Volume | 618,314 | 28,758,237 |
Sector | Health | — |
52-Week High | $275.96 | $47.73 |
52-Week Low | $182.82 | $39.25 |
Typical Hold Time | 51 Days | 80 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
XLU trades at $41.07, down 0.19% on the day, as utility stocks face pressure from rising interest rates. The ETF recently hit 52-week lows amid sector-wide selling, though technical indicators show a mixed picture with bullish moving averages but neutral oscillators. Recent news highlights oversold conditions in utilities, with the sector experiencing its steepest monthly drop in nearly two years according to 24/7 Wall Street (2026-10-02).
The outlook remains challenged by interest rate sensitivity, but defensive characteristics could provide support if economic uncertainty persists. Key risks include continued rate hikes and regulatory headwinds, while potential catalysts include defensive rotation during market volatility and AI-driven power demand growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →